8-KMaterial AgreementsOther EventsExhibits & Filings

Merck & Co., Inc. 8-K Report, Material Agreement (Oct 2, 2007)

Filed October 2, 2007For Securities:MRK

Summary

This 8-K filing by Schering-Plough Corporation (operating under Merck & Co. at the time, as the filing date precedes their merger announcement) details two significant financial transactions. The company has entered into a definitive agreement to acquire the human and animal health businesses of Akzo Nobel N.V. for approximately €11 billion in cash, a move that signals a major expansion and strategic acquisition for Schering-Plough. This transaction is a key indicator of the company's growth strategy and its commitment to strengthening its position in the pharmaceutical and healthcare sectors. In parallel, Schering-Plough announced the pricing of a substantial Euro-denominated senior notes offering, raising €500 million in 5.000% Senior Notes due 2010 and €1.5 billion in 5.375% Senior Notes due 2014. These funds are likely intended to finance the aforementioned acquisition and potentially other corporate initiatives. The filing includes the necessary agreements and legal opinions related to both the acquisition and the debt issuance, providing transparency to investors about these material events.

Key Highlights

  • 1Schering-Plough has entered into a definitive Share Purchase Agreement to acquire Akzo Nobel N.V.'s human and animal health businesses for approximately €11 billion in cash.
  • 2The acquisition is a material definitive agreement, signaling a significant strategic move for Schering-Plough.
  • 3Schering-Plough has priced a senior notes offering, raising €500 million in 5.000% Senior Notes due 2010.
  • 4An additional €1.5 billion was raised through 5.375% Senior Notes due 2014.
  • 5The debt issuance is intended to support the company's financing needs, likely including the Akzo Nobel acquisition.
  • 6The filing incorporates various exhibits, including the Underwriting Agreement, Supplemental Indenture, and the Share Purchase Agreement, providing detailed documentation for investors.
  • 7This 8-K is being used to incorporate by reference into Schering-Plough's Registration Statement on Form S-3.

Frequently Asked Questions

This 8-K filing discloses two primary financial events for Schering-Plough: a significant acquisition of Akzo Nobel N.V.'s human and animal health businesses for approximately €11 billion in cash, and the pricing of a large Euro-denominated senior notes offering totaling €2 billion.

While the filing doesn't explicitly state the financing source for the entire €11 billion acquisition, it does detail a concurrent senior notes offering of €2 billion. It is highly probable that the proceeds from this debt issuance are intended to partially or fully fund the acquisition, along with other potential financing sources.

Schering-Plough announced the pricing of two tranches of senior notes: €500 million aggregate principal amount of 5.000% Senior Notes due 2010, and €1.5 billion aggregate principal amount of 5.375% Senior Notes due 2014.

Schering-Plough is filing this 8-K to report on the material definitive agreement for the acquisition and to provide information related to its senior notes offering. Additionally, it's incorporating by reference several documents, including agreements and legal opinions, into its existing Registration Statement on Form S-3 for public offering purposes.